Genocea Biosciences, Inc. (GNCA)

June 3, 2022 - GNCA was delisted (reason: commenced wind down)
0.0510
-0.0090 (-15.00%)
At close: Jun 2, 2022 4:00 PM
0.0550
+0.0040 (7.8431%)
After-hours: Jun 2, 2022 7:59 PM EDT
-15.00%
Market Cap 3.00M
Revenue (ttm) 1.91M
Net Income (ttm) -37.19M
Shares Out 58.78M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 266,749
Open 0.0165
Previous Close 0.0600
Day's Range 0.0500 - 0.0605
52-Week Range 0.0120 - 2.4100
Beta 1.89
Analysts Buy
Price Target 3.14 (+6,056.9%)
Earnings Date Jul 27, 2022

About GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2014
CEO William Clark
Employees 74
Stock Exchange NASDAQ
Ticker Symbol GNCA
Full Company Profile

Financial Performance

In 2021, GNCA's revenue was $1.64 million, an increase of 20.75% compared to the previous year's $1.36 million. Losses were -$33.20 million, -24.06% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for GNCA stock is "Buy." The 12-month stock price forecast is 3.14, which is an increase of 6,056.86% from the latest price.

Price Target
$3.14
(6,056.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.

Genocea Biosciences (GNCA) stock is on the move Wednesday after the bioscience company revealed its shutting down and delisting shares. The post Genocea Biosciences Is Shutting Down.

Genocea Biosciences to shut down

Genocea Biosciences Inc. GNCA, -72.69% on Tuesday told investors it plans to shut down and lay off all remaining employees. The company said it gave notice to The Nasdaq Stock Market Inc. for its plans ...

Genocea Closes Shop, Delists From NASDAQ

Genocea Biosciences Inc's (NASDAQ: GNCA) board has voted to wind down the company's ongoing operations and terminate the remaining employees except those deemed necessary to complete an orderly wind dow...

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board o...

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it ...

Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes

What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information...

Other symbols: AIMHOTH

Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients

Genocea Biosciences Inc (NASDAQ: GNCA) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at Ameri...

Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chi...

Genocea Provides Fourth Quarter 2021 Corporate Update

Initial GEN-011 clinical trial data to be presented at AACR

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea's neoantigen-targeted peripheral T cell therapy for solid tumors

John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors

CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Joh...

Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its fourth quarter...

Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip...

Genocea to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior lea...

Genocea Biosciences Provides Corporate Update

Enters into Inhibigen™ R&D collaboration and option agreement with Janssen

Genocea to Present at the Stifel 2021 Virtual Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip...

Genocea Provides Third Quarter 2021 Corporate Update

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues

Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third quarter 2...

Genocea to Present at Upcoming Conferences

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior le...

Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jen...

Genocea to Present at Upcoming Scientific and Investor Conferences

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior le...

Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?

Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.

Genocea Provides Second Quarter 2021 Corporate Update

GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues

Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second quarter ...